CLAIMS

1. A dispersible tablet comprising Compound I of the formula



or a pharmaceutically acceptable salt thereof present in an amount of from 5% to 40% in weight based on the total weight of the tablet.

2. A dispersible tablet comprising (a) Compound I or a pharmaceutically acceptable salt thereof, and (b) at least one pharmaceutically acceptable excipient suitable for the preparation of tablets, wherein Compound I or a pharmaceutically acceptable salt thereof is present in an amount of from 5% to 40% in weight based on the total weight of the tablet.

3. A dispersible tablet comprising an iron-chelating pharmacologically effective amount of Compound I or a pharmaceutically acceptable salt thereof present in an amount of from 5% to 40% in weight based on the total weight of the tablet.

4. The dispersible tablet according to claim 1, 2 or 3 wherein Compound I is in the free acid form.

5. The dispersible tablet according to any one of claims 1 to 4 wherein Compound I is in a crystalline form.

6. The dispersible tablet according to any one of claims 1 to 5 wherein a lubricant is present in less than 1% in weight based on the total weight of the tablet.

7. The dispersible tablet according to claim 6 wherein the lubricant is present in less than 0.4% in weight based on the total weight of the tablet.

8. The dispersible tablet according to any one of claims 1 to 7 wherein the disintegration time of the tablet is of 5 minutes or less.

9. The dispersible tablet according to any one of claims 1 to 8 wherein the disintegration time of the tablet is of 3 minutes or less.

10. The dispersible tablet according to any one of claims 2 to 9 wherein the pharmaceutically acceptable excipients comprise:
(i) at least one filler in a total amount of about 35 to 55 % in weight based on the total weight of the tablet,
(ii) at least one disintegrant in a total amount of about 10% to 35% in weight based on the total weight of the tablet
(iii) at least one binder in a total amount of about 1.5% to 5% in weight based on the total weight of the tablet,
(iv) at least one surfactant in a total amount of about 0.2% to 1% in weight based on the total weight of the tablet,
(v) at least one glidant in a total amount of about 0.1% to 0.5% in weight based on the total weight of the tablet, and/or
(vi) at least one lubricant in a total amount of less than about 0.4% in weight based on the total weight of the tablet.

11. The dispersible tablet according to any one of claims 6 to 10 wherein the lubricant is magnesium stearate.

12. The dispersible tablet according to anyone of claims 1 to 11 containing Compound I in its free acid form in an amount of about 100 mg to 600 mg .

13. A method of administering to a mammal in need of such a treatment a daily dose of 5 to 40 mg/kg of body weight of Compound I as active ingredient.

14. A process for the preparation of the dispersible tablet according to any one of the preceding claims, which process comprises
(i) mixing the Compound I or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient;

(ii) wet-granulating the mixture obtained in (i);

(iii) mixing the granulates obtained in (ii) with at least one pharmaceutically acceptable excipient to form a mixture; and

(iv) spraying the lubricant on the materials contacting surfaces of pressing tools of the tabletting machine and compressing the mixture obtained in step (iii) to form a tablet.

15. The process according to claim 14 wherein the lubricant is magnesium stearate.